HLS Therapeutics (TSE:HLS) Price Target Raised to C$5.00

HLS Therapeutics (TSE:HLS) had its target price hoisted by research analysts at Raymond James from C$4.00 to C$5.00 in a note issued to investors on Friday,BayStreet.CA reports. Raymond James’ price objective points to a potential upside of 46.20% from the stock’s previous close.

Separately, Stifel Nicolaus lowered their price target on HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.

HLS Therapeutics Trading Up 3.3 %

TSE HLS opened at C$3.42 on Friday. The firm’s 50 day moving average price is C$3.54 and its two-hundred day moving average price is C$3.50. The company has a debt-to-equity ratio of 100.44, a quick ratio of 1.01 and a current ratio of 2.02. HLS Therapeutics has a twelve month low of C$3.00 and a twelve month high of C$5.48. The stock has a market cap of C$108.72 million, a price-to-earnings ratio of -3.39 and a beta of 1.07.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.